Compare ELS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELS | CYTK |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 10.7B |
| IPO Year | 1994 | 2004 |
| Metric | ELS | CYTK |
|---|---|---|
| Price | $65.42 | $80.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $70.25 | ★ $89.26 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 2.55 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $1,531,382,000.00 | $13,368,000.00 |
| Revenue This Year | $3.97 | $7.37 |
| Revenue Next Year | $4.69 | $310.19 |
| P/E Ratio | $116.16 | ★ N/A |
| Revenue Growth | ★ 0.34 | N/A |
| 52 Week Low | $57.63 | $32.89 |
| 52 Week High | $69.00 | $88.31 |
| Indicator | ELS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 52.43 |
| Support Level | $61.39 | $59.07 |
| Resistance Level | $65.96 | $88.31 |
| Average True Range (ATR) | 1.34 | 3.03 |
| MACD | 0.07 | -0.59 |
| Stochastic Oscillator | 62.99 | 40.34 |
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company has a portfolio of 453 properties across the US with a higher concentration in the Sun Belt; 38% of its properties are in Florida, 11% in Arizona, and 10% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.